Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
09637 禮邦醫藥－Ｂ
ALEBUND-B
Listing Date2026/06/29    Listing in 3 Days
Listing Price22.600
Grey Market Performance
Last updated: 26/06/2026 19:59  Refresh
  • Bright Smart
    up 42.180 +19.580 (+86.637%)
    High
    44.100
     
    Low
    30.100
    Volume
    69,200
    One Lot Profit
    +1,958.00
  • Phillip
    up 43.880 +21.280 (+94.159%)
    High
    44.880
     
    Low
    38.000
    Volume
    1,980,000
    One Lot Profit
    +2,128.00
  • Futu
    up 42.500 +19.900 (+88.053%)
    High
    43.720
     
    Low
    23.260
    Volume
    3,645,000
    One Lot Profit
    +1,990.00
  • Bid
  • Ask
  • 42.180
  • (1) 100
  • 800 (4)
  • 43.800
  • 42.160
  • (0) 0
  • 200 (1)
  • 43.820
  • 42.140
  • (0) 0
  • 500 (1)
  • 43.840
  • 42.120
  • (0) 0
  • 0 (0)
  • 43.860
  • 42.100
  • (0) 0
  • 300 (3)
  • 43.880
  • 42.080
  • (0) 0
  • 0 (0)
  • 43.900
  • 42.060
  • (1) 100
  • 0 (0)
  • 43.920
  • 42.040
  • (1) 400
  • 0 (0)
  • 43.940
  • 42.020
  • (0) 0
  • 0 (0)
  • 43.960
  • 42.000
  • (0) 0
  • 100 (1)
  • 43.980
  • Bid
  • Ask
  • 43.840
  • (5) 4K
  • 1.8K (7)
  • 43.900
  •  
  • (9) 9.4K
  • 0 (0)
  •  
  •  
  • (11) 8.6K
  • 300 (1)
  •  
  •  
  • (4) 4.5K
  • 200 (2)
  •  
  •  
  • (0) 0
  • 600 (6)
  •  
 
Hide
COMPANY PROFILE

Alebund Pharmaceuticals (Jiangsu) Ltd. was founded in 2018, it is a biopharmaceutical company providing renal therapies.

--

The Group’s product portfolio in clinical and preclinical stages consists of one Core Product AP301 and six other product candidates, including one late-clinical-stage product candidate (AP306), one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307) as of June 12, 2026.

--

The Group’s sole Core Product, AP301 is classified as a Class 1 new chemical drug in China and it is a phosphate binder for the treatment of hyperphosphatemia. AP306 is a differentiated pan-phosphate transporter inhibitor for hyperphosphatemia in CKD patients receiving dialysis.

--

As of June 12, 2026, the Group held 153 patents and patent applications, among which 24 were related to its Core Product. The Group has completed the construction of an in-house manufacturing facility in Yangzhou, China, and its revenue was generated from a single customer, which is its distributor for Mircera in China.

BASIC INFORMATION
MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot100
GLOBAL OFFERING
No. of Offer Shares56.76M H shares
No. of International Offer Shares51.08M H shares
No. of HK Offer Shares5.68M H shares
Offer Price$22.60
Stock Code9637
Sponsor(s)Jefferies Hong Kong Limited, Merrill Lynch (Asia Pacific) Limited, Huatai Financial Holdings (Hong Kong) Limited
Underwriter(s)Jefferies Hong Kong Limited, Merrill Lynch (Asia Pacific) Limited, Huatai Financial Holdings (Hong Kong) Limited, CLSA Limited, BOCI Asia Limited
TIME TABLE
Application PeriodJun 18 (Thu) - noon, Jun 24 (Wed)
Price Determination Date--
Result Announcement DateOn or before Jun 26 (Fri)
Result Announcement DateOn or before Jun 26 (Fri)
Result Announcement DateOn or before Jun 29 (Mon)
Dealings in Shares commence onJun 29, 2026. (Mon)
Reallocation of Shares Offered
Sales Statistics (HKD)
Offer Price$22.60
Capitalization (H Shares)5.13B
NAV / share ($)$5.21 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 22.6, the net proceeds raised would be HKD 1.18B, of which
71% : AP301 evolving business needs and changing market conditions
7% : Other product candidates evolving business needs
12% : Commercialization of drug candidates after approved for sale
10% : Working capital
IPO NEWS
26/06/2026 18:35
{New Stock}ALEBUND-B(09637) ends up 94.16% on grey market
26/06/2026 16:20
{New Stock}ALEBUND-B up 91.86% at HK$43.36 on grey market
Related Document
Prospectus Prospectus  Chinese VersionProspectus  English Version
Remark： The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
 :
Subscribing Lot :
Subscribing Fee :
Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2026 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.